DCT – Decentralized Clinical Trials
This event focuses on the challenges and opportunities that accompany hybrid and fully decentralized clinical trial case studies. Meet with sponsors, solution providers and key associations, as well as the world-renowned speaker panel to understand the vital components of planning and conducting decentralized or hybrid clinical studies. Learn about the role that digital technology plays in improving the diversity and inclusion of clinical trials while networking with innovators from pharma, biotech, medical device, regulator, patient group and other key stakeholders.
Session Information:
Title: Ensuring Rich Evidence in DCTs in a World that Demands Trial Anywhere™
Date: Tuesday, June 7th, 2022
Time: 4:30 p.m. – 5:00 p.m. EST
With only 5-10% of clinical trials expected to be fully decentralized and 70-80% expected to be hybrid, sponsors, sites and CROs need to continue to solve the challenges of generating rich evidence in this decentralized reality. While capturing high-quality data might meet regulatory standards, rich evidence determines the safety and efficacy of a medicine, medical device, or therapy. Generating rich, gold-standard evidence requires a fusion of scientific and technological excellence. Learn how therapeutic area and domain expertise augments evidence-generating technologies and methodologies. This session will address:
- The impacts of decentralized and hybrid trials on clinical evidence generation
- The influences of patient accountability
- How science drives rich evidence
- The impact of rich evidence on studies
Speakers
Bryan McDowell
VP, eCOA Science & Consulting at Clario
In his role as VP, eCOA Science & Consulting, Bryan brings extensive experience and expertise to achieve smarter drug development, clinical trial design and execution (including decentralized and remote trials) to vastly expand the reach and access of trials to more patients, provide improved patient experience and data quality to deliver accelerated drug & device development programs. Bryan is a thought leader and recognized strategist & visionary and continues to influence, drive and deliver on the pharma wide industry necessity for smarter drug & device development and life cycle management.
Todd Rudo, MD
VP, Cardiology and Deputy Chief Medical Officer
Dr. Todd Rudo is the Deputy Chief Medical Officer at Clario, with board certifications in cardiology, cardiac electrophysiology, nuclear cardiology, and adult echocardiography. He completed his general medical training at Jefferson Medical College in Philadelphia, PA, and specialty training at Lankenau Medical Center in Wynnewood, PA. After transitioning from private practice, Dr. Rudo has focused his career on drug safety / pharmacovigilance with responsibilities across multiple therapeutic areas within large and medium-size pharmaceutical companies. In his current role, he primarily supports cardiac safety consultative services, in addition to oversight of ECG core lab activities.